PositiveID Corporation to Exhibit at the AMSUS Federal Health 2016 Conference

PositiveID to exhibit its Caregiver non-contact thermometer and Firefly Dx point-of-need pathogen detection system

DELRAY BEACH, Fla., Nov. 14, 2016 (GLOBE NEWSWIRE) -- PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a life sciences company focused on detection and diagnostics, announced today that it will exhibit its Caregiver® non-contact, infrared thermometer and its Firefly Dx point-of-need pathogen detection system at the AMSUS Federal Health 2016 Conference at the Gaylord National Resort and Convention Center in National Harbor, MD from November 29-December 2, 2016.

Caregiver is a clinical-grade, infrared thermometer for measurement of forehead temperature in adults, children, and infants without contact. It delivers an oral-equivalent temperature directly from the forehead in one to two seconds. Since Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs. It is estimated that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone.

PositiveID is developing the Firefly Dx polymerase chain reaction (“PCR”) prototype system to be a handheld, fully automated, lab quality, real-time device able to detect bio-threats at the point of need. Currently, PCR tests are run on large lab equipment and take a minimum of four hours to deliver results. A design advantage of Firefly Dx is that it does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test.

AMSUS - the Society of Federal Health Professionals - was established in 1891 and chartered by an Act of Congress in 1903. The medical services of the Department of Defense, Department of Veterans Affairs, Department of Health and Human Services, Department of Homeland Security and the medical departments other federal agencies form the constituency of the Association. AMSUS’ objectives are to advance the knowledge of federal and military medicine, to increase the efficiency of its membership by providing a forum for discussion of common ideas and issues, and provide continuing education opportunities for its members.

About PositiveID Corporation
PositiveID Corporation is a life sciences tools and diagnostics company with an extensive patent portfolio. PositiveID develops biological detection and diagnostics systems, specializing in the development of microfluidic systems for the automated preparation of and performance of biological assays. PositiveID is also a leader in the mobile technology vehicle market, with a focus on the laboratory market and homeland security. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

Statements about PositiveID's future expectations, including the likelihood that since there is no skin contact and Caregiver does not require probe cover supplies, it reduces the risk of cross-contamination, which is an increasing concern, and saves healthcare facilities the cost of covers (as much as $0.05 to $0.10 per temperature), storage space, and waste disposal costs; the likelihood that Caregiver can offer savings of $250 or more per year per device in probe cover supplies alone; the likelihood that Firefly Dx does not require additional equipment or separate steps for sample preparation and purification, unlike current lab-based equipment, thus reducing time to results as well as cost per test; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company’s ability to target the professional healthcare market, as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on April 12, 2016, and 10-Qs filed on August 12, 2016, May 16, 2016, and November 12, 2015, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contacts:
                    PositiveID Corporation
                    Allison Tomek
                    (561) 805-8044
                    atomek@psidcorp.com
                    
                    RedChip Companies
                    Jon Cunningham
                    (407) 644-4256
                    jon@redchip.com